Literature DB >> 24112243

In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex.

M Lavollay1, V Dubée, B Heym, J-L Herrmann, J-L Gaillard, L Gutmann, M Arthur, J-L Mainardi.   

Abstract

The in vitro activity of cefoxitin and imipenem was compared for 43 strains of the Mycobacterium abscessus complex, mostly isolated from cystic fibrosis patients. The MICs of imipenem were lower than those of cefoxitin, although the number of imipenem-resistant strains was higher according to the CLSI breakpoints. Strain comparisons indicated that the MICs of cefoxitin were significantly higher for Mycobacterium bolletii than for M. abscessus. The MICs of both β-lactams were higher for the rough morphotype than for the smooth morphotype. The clinical impact of the in vitro difference between the activity of imipenem and that of cefoxitin remains to be determined.
© 2013 The Authors Clinical Microbiology and Infection © 2013 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Antimicrobial susceptibility; Mycobacterium abscessus; cefoxitin; cystic fibrosis; imipenem

Mesh:

Substances:

Year:  2013        PMID: 24112243     DOI: 10.1111/1469-0691.12405

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  29 in total

1.  β-Lactam Combinations That Exhibit Synergy against Mycobacteroides abscessus Clinical Isolates.

Authors:  Elizabeth Story-Roller; Christos Galanis; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

2.  Preclinical Pharmacokinetic and Pharmacodynamic Data To Support Cefoxitin Nebulization for the Treatment of Mycobacterium abscessus.

Authors:  Shachi Mehta; Vincent Aranzana-Climent; Blandine Rammaert; Nicolas Grégoire; Sandrine Marchand; William Couet; Julien M Buyck
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

3.  Synergistic Efficacy of β-Lactam Combinations against Mycobacterium abscessus Pulmonary Infection in Mice.

Authors:  Elizabeth Story-Roller; Emily C Maggioncalda; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  Select β-Lactam Combinations Exhibit Synergy against Mycobacterium abscessus In Vitro.

Authors:  Elizabeth Story-Roller; Emily C Maggioncalda; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

5.  Inhibition of the β-Lactamase BlaMab by Avibactam Improves the In Vitro and In Vivo Efficacy of Imipenem against Mycobacterium abscessus.

Authors:  Anne-Laure Lefebvre; Vincent Le Moigne; Audrey Bernut; Carole Veckerlé; Fabrice Compain; Jean-Louis Herrmann; Laurent Kremer; Michel Arthur; Jean-Luc Mainardi
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 6.  Repositioning rifamycins for Mycobacterium abscessus lung disease.

Authors:  Uday S Ganapathy; Véronique Dartois; Thomas Dick
Journal:  Expert Opin Drug Discov       Date:  2019-06-14       Impact factor: 6.098

7.  In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system.

Authors:  Audrey Bernut; Vincent Le Moigne; Tiffany Lesne; Georges Lutfalla; Jean-Louis Herrmann; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

8.  Impact of β-lactamase inhibition on the activity of ceftaroline against Mycobacterium tuberculosis and Mycobacterium abscessus.

Authors:  Vincent Dubée; Daria Soroka; Mélanie Cortes; Anne-Laure Lefebvre; Laurent Gutmann; Jean-Emmanuel Hugonnet; Michel Arthur; Jean-Luc Mainardi
Journal:  Antimicrob Agents Chemother       Date:  2015-03-02       Impact factor: 5.191

9.  Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus.

Authors:  Amit Kaushik; Chhavi Gupta; Stefanie Fisher; Elizabeth Story-Roller; Christos Galanis; Nicole Parrish; Gyanu Lamichhane
Journal:  Future Microbiol       Date:  2017-02-16       Impact factor: 3.165

10.  Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.

Authors:  Amit Kaushik; Nayani Makkar; Pooja Pandey; Nicole Parrish; Urvashi Singh; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.